West Pharmaceutical Services, Inc. $WST Shares Acquired by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP increased its West Pharmaceutical Services stake by 8.7% in the second quarter, bringing its holdings to 64,490 shares valued at approximately $23.2 million.
• Institutional investors own 93.9% of WST, while Vice President Annette Favorite sold 8,135 shares for about $2.77 million, reducing her holdings by 32.6%.
• West Pharmaceutical Services beat quarterly earnings and revenue estimates, reporting $2.37 EPS and $872.3 million in revenue. Analysts maintain a “Moderate Buy” consensus with an average price target of $373.85.

Corient Private Wealth LP grew its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 8.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,490 shares of the medical instruments supplier's stock after purchasing an additional 5,161 shares during the period. Corient Private Wealth LP owned about 0.09% of West Pharmaceutical Services worth $23,152,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. California State Teachers Retirement System lifted its stake in West Pharmaceutical Services by 36,590.8% during the second quarter. California State Teachers Retirement System now owns 40,592,489 shares of the medical instruments supplier's stock valued at $14,572,704,000 after buying an additional 40,481,855 shares in the last quarter. BlackRock Inc. purchased a new position in shares of West Pharmaceutical Services in the second quarter worth approximately $2,387,990,000. Bank of New York Mellon Corp acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $733,733,000. Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $728,168,000. Finally, Norges Bank acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $272,041,000. Institutional investors and hedge funds own 93.90% of the company's stock.

Insider Activity

In related news, VP Annette Favorite sold 8,135 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares in the company, valued at approximately $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company's stock.

West Pharmaceutical Services Stock Performance

WST stock opened at $345.49 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The stock has a market cap of $24.32 billion, a P/E ratio of 44.24, a P/E/G ratio of 2.42 and a beta of 1.14. The firm has a 50 day simple moving average of $348.46 and a 200 day simple moving average of $310.74. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the firm posted $1.84 earnings per share. The firm's revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were paid a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio is 11.27%.

Analysts Set New Price Targets

A number of research firms recently commented on WST. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They issued an "outperform" rating and a $447.00 price objective for the company. Weiss Ratings raised shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 7th. Stephens restated an "overweight" rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Barclays raised West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Finally, UBS Group lifted their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $373.85.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc NYSE: WST develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company's offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.